Humayun Ashraf, MD
Pulmonary Disease · Hutchinson, KSNPI 1184980765
Payments from drug & device makers
Across 266 payments — averaging $50.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Veran Medical Technologies, Inc.$968
- Boehringer Ingelheim$896
- GSK$893
- AstraZeneca$689
- United Therapeutics Corporation$287
- plus $2K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $7,300 |
| Veran Medical Technologies, Inc. | 3 | $968 |
| Boehringer Ingelheim | 28 | $896 |
| GSK | 53 | $893 |
| AstraZeneca | 32 | $689 |
| United Therapeutics Corporation | 14 | $287 |
| Genentech USA, Inc. | 11 | $229 |
| Actelion Pharmaceuticals US, Inc. | 8 | $224 |
| Grifols USA, LLC | 9 | $214 |
| Mylan Specialty L.p. | 9 | $162 |
| Sunovion Pharmaceuticals Inc. | 15 | $154 |
| Inspire Medical Systems, Inc. | 7 | $121 |
| Regeneron Healthcare Solutions, Inc. | 6 | $114 |
| Amgen(2 entities) | 6 | $114 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Sanofi | 3 | $91 |
| Inari Medical, Inc. | 1 | $90 |
| Novartis | 5 | $88 |
| Harmony Biosciences LLC | 5 | $88 |
| Verona Pharma, Inc. | 5 | $88 |
| Philips North America LLC | 3 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| ZOLL Respicardia, Inc. | 2 | $58 |
| Pfizer | 3 | $51 |
| Merck | 3 | $45 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| Sanofi US Services Inc. | 1 | $39 |
| Viatris Specialty LLC | 2 | $36 |
| Insmed, Inc. | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $30 |
| AbbVie | 2 | $29 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Electromed, Inc. | 2 | $21 |
| Hospira, Inc. | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Resmed Corp | 1 | $13 |
How this compares
$13,515 in reported general payments places this provider in the 75th percentile of 92 pulmonary disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Hutchinson
- Robert SourkHutchinson$33K
- Moh'd Al-HalawaniHutchinson$15K
- Mario CastroKansas City$3.8M
- Andreas SchmidKansas City$2M
- Sahil PandyaKansas City$1.1M
- Matthew SharpeKansas City$602K
- Joel MermisKansas City$360K
- Chase HallKansas City$329K
- Maykol Postigo JasahuiKansas City$322K
- Avinash SinghManhattan$307K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.